Lucas Villas Bôas Hoelz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lucas Villas Bôas Hoelz has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Nubia Boechat
FIOCRUZ
7 shared publications - Frederico Silva Castelo Branco
FIOCRUZ
3 shared publications - Monica Macedo Bastos
FIOCRUZ
3 shared publications - Tácio Vinício Amorim Fernandes
FIOCRUZ
3 shared publications - Bruna Costa Zorzanelli
Universidade Estácio de Sá
2 shared publications - Caroline Rodrigues Chaves dos Reis
Fundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós‐Graduação em Pesquisa Translacional em Fármacos e Medicamentos Rio de Janeiro RJ Brazil
2 shared publications
Latest Publications
- 6 October 2026
- Published by Taylor & Francis in Molecular Simulation
- Vol. 52 (16) , 1558-1575
Conformational dynamics and energetic landscape of the SARS-CoV-2 nsp12 with and without accessory proteins: new insights on this potential therapeutic target against COVID-19
- 6 October 2026
- Published by Taylor & Francis in Molecular Simulation
- Vol. 52 (16) , 1558-1575
Conformational dynamics and energetic landscape of the SARS-CoV-2 nsp12 with and without accessory proteins: new insights on this potential therapeutic target against COVID-19
- Open Access
- 14 June 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (6) , e70340
Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.
- 14 June 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (6) , e70340
Open AccessCruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.
- 27 April 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (10) , 4368-4382
Study of the dynamic behavior of the cruzain enzyme in free and complexed forms with competitive and noncovalent benzimidazole inhibitors
There are only two drugs for the treatment of Chagas disease, namely, nifurtimox and benznidazole, that can cause several adverse effects. Despite the effectiveness of these drugs in the disease's acute phase, they are not recognized as curative in the chronic phase, establishing the need for more effective treatment in all stages of the disease. Cruzain is an enzyme that plays a vital role in the life cycle of the etiologic agent, the protozoan Trypanosoma cruzi, being relevant as a therapeutic target in the planning of new drugs. Using molecular docking and dynamics simulations, we have investigated the structural and dynamic factors that can be involved in the enzyme inhibition process at the atomic-molecular level by benzimidazole compounds that are potent cruzain inhibitors with in vitro trypanocidal activity. The study suggests that these inhibitors bind cruzain through steric and hydrogen bonding interactions without altering its secondary structure content and protein compaction. Besides, we observed that these inhibitors decrease the correlation of movements between Cα-atoms of cruzain, increasing the number of atomic communities, mainly in the α-helix that presents the catalytic Cys25 residue. As expected, we also observed a correlation between the inhibitory activity of each inhibitor and their respective binding-free energies, reinforcing that the affinity of the complexes seems to be a relevant factor for enzymatic inhibition. Hence, the results presented in this work contribute to a better understanding of the cruzain enzyme inhibition mechanism through competitive and non-covalent inhibitors. Communicated by Ramaswamy H. Sarma
- 27 April 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (10) , 4368-4382
Study of the dynamic behavior of the cruzain enzyme in free and complexed forms with competitive and noncovalent benzimidazole inhibitors
There are only two drugs for the treatment of Chagas disease, namely, nifurtimox and benznidazole, that can cause several adverse effects. Despite the effectiveness of these drugs in the disease's acute phase, they are not recognized as curative in the chronic phase, establishing the need for more effective treatment in all stages of the disease. Cruzain is an enzyme that plays a vital role in the life cycle of the etiologic agent, the protozoan Trypanosoma cruzi, being relevant as a therapeutic target in the planning of new drugs. Using molecular docking and dynamics simulations, we have investigated the structural and dynamic factors that can be involved in the enzyme inhibition process at the atomic-molecular level by benzimidazole compounds that are potent cruzain inhibitors with in vitro trypanocidal activity. The study suggests that these inhibitors bind cruzain through steric and hydrogen bonding interactions without altering its secondary structure content and protein compaction. Besides, we observed that these inhibitors decrease the correlation of movements between Cα-atoms of cruzain, increasing the number of atomic communities, mainly in the α-helix that presents the catalytic Cys25 residue. As expected, we also observed a correlation between the inhibitory activity of each inhibitor and their respective binding-free energies, reinforcing that the affinity of the complexes seems to be a relevant factor for enzymatic inhibition. Hence, the results presented in this work contribute to a better understanding of the cruzain enzyme inhibition mechanism through competitive and non-covalent inhibitors. Communicated by Ramaswamy H. Sarma
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 21 (23) , 2072-2100
The Medicinal Chemistry of 3-nitro-1,2,4-triazoles: Focus on Infectious Diseases
: Infectious diseases are among the leading causes of death worldwide, especially in developing countries. The historical lack of interest of the pharmaceutical industry in developing new drugs against many of these diseases, such as tuberculosis, leishmaniasis, Chagas disease, sleeping sickness, and fungal infections, has left millions of individuals dependent on old treatments that are often ineffective and present different adverse effects. In this sense, new substances against these diseases must be identified. A class of substances that has stood out in the search for new drugs against these diseases is azole derivatives. Within this class, the 3-nitro-1,2,4-triazole nucleus has attracted increasing interest due to its potential, specifically when compared to the 1,2,4-triazole nucleus without the presence of the nitro group, and also in relation to the 2-nitroimidazole nucleus, showing greater potency and selectivity against different etiological agents. This is even more relevant considering that 3-nitro-1,2,4-triazolic substances can promote their activity through different mechanisms of action, such as the inhibition of ergosterol biosynthesis and also via activation by the nitroreductase enzyme, which can avoid the development of cross-resistance. Therefore, in this review, the medicinal chemistry of nitrotriazoles is discussed through the analysis of their potential in terms of biological activity against the etiological agents of several diseases, such as Chagas disease, sleeping sickness and leishmaniasis, caused by kinetoplastid parasites, tuberculosis, caused by the mycobacteria Mycobacterium tuberculosis, and against different species of pathogenic fungi. In addition, aspects related to enzymatic activities, molecular modeling and organic synthesis of these substances are also addressed.
- 1 September 2021
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 21 (23) , 2072-2100
The Medicinal Chemistry of 3-nitro-1,2,4-triazoles: Focus on Infectious Diseases
: Infectious diseases are among the leading causes of death worldwide, especially in developing countries. The historical lack of interest of the pharmaceutical industry in developing new drugs against many of these diseases, such as tuberculosis, leishmaniasis, Chagas disease, sleeping sickness, and fungal infections, has left millions of individuals dependent on old treatments that are often ineffective and present different adverse effects. In this sense, new substances against these diseases must be identified. A class of substances that has stood out in the search for new drugs against these diseases is azole derivatives. Within this class, the 3-nitro-1,2,4-triazole nucleus has attracted increasing interest due to its potential, specifically when compared to the 1,2,4-triazole nucleus without the presence of the nitro group, and also in relation to the 2-nitroimidazole nucleus, showing greater potency and selectivity against different etiological agents. This is even more relevant considering that 3-nitro-1,2,4-triazolic substances can promote their activity through different mechanisms of action, such as the inhibition of ergosterol biosynthesis and also via activation by the nitroreductase enzyme, which can avoid the development of cross-resistance. Therefore, in this review, the medicinal chemistry of nitrotriazoles is discussed through the analysis of their potential in terms of biological activity against the etiological agents of several diseases, such as Chagas disease, sleeping sickness and leishmaniasis, caused by kinetoplastid parasites, tuberculosis, caused by the mycobacteria Mycobacterium tuberculosis, and against different species of pathogenic fungi. In addition, aspects related to enzymatic activities, molecular modeling and organic synthesis of these substances are also addressed.
- Open Access
- 29 July 2020
- Published by Oxford University Press (OUP) in Letters in Applied Microbiology
- Vol. 71 (6) , 645-651
Synthesis of benzoylthiourea derivatives and analysis of their antibacterial performance against planktonic Staphylococcus aureus and its biofilms
Following the appearance of several antimicrobial agents to control the spread of infections, two major challenges have emerged: 1‐ the occurrence and blowout of multiresistant bacteria and the increase of chronic diseases, and 2‐ difficult‐to‐eradicate infections. In this study, we tested five benzoylthiourea derivatives for their ability to inhibit and stop bacterial growth and evaluated the possible influence of 1,2,4‐triazolyl‐benzoylthiourea derivative 4 on the formation and eradication of S. aureus biofilms. Benzoylthiourea derivatives 4 , 6 , 10 , 11, and 13 were obtained in one or two steps with low cost and subjected to tests to identify their minimum inhibitory concentration and minimum bactericidal concentration. In vitro tests were also performed to assess their effects on biofilm formation and in preformed biofilms and scanning electron microscopy was used to visualize the effects on biofilm formation. The 1,2,4‐triazolyl‐benzoylthiourea derivative 4 showed bacteriostatic activity against the Staphylococcus aureus HU25 clinical strain with an minimum inhibitory concentration (MIC) of 16 µg.mL‐1, which is below the toxic concentration (at 2,500 µg.mL‐1, 62.25% of the cells remained viable). Compound 4 also effectively prevented biofilm formation at the three subinhibitory concentrations tested (1/2 MIC, 1/4 MIC and 1/8 MIC) as confirmed by SEM. For breakdown of formed biofilms, the main influence was at a subinhibitory concentration (1/2 MIC). These findings make compound 4 a strong candidate for studies on the development of new antimicrobial and antibiofilm agents.
- 29 July 2020
- Published by Oxford University Press (OUP) in Letters in Applied Microbiology
- Vol. 71 (6) , 645-651
Open AccessSynthesis of benzoylthiourea derivatives and analysis of their antibacterial performance against planktonic Staphylococcus aureus and its biofilms
Following the appearance of several antimicrobial agents to control the spread of infections, two major challenges have emerged: 1‐ the occurrence and blowout of multiresistant bacteria and the increase of chronic diseases, and 2‐ difficult‐to‐eradicate infections. In this study, we tested five benzoylthiourea derivatives for their ability to inhibit and stop bacterial growth and evaluated the possible influence of 1,2,4‐triazolyl‐benzoylthiourea derivative 4 on the formation and eradication of S. aureus biofilms. Benzoylthiourea derivatives 4 , 6 , 10 , 11, and 13 were obtained in one or two steps with low cost and subjected to tests to identify their minimum inhibitory concentration and minimum bactericidal concentration. In vitro tests were also performed to assess their effects on biofilm formation and in preformed biofilms and scanning electron microscopy was used to visualize the effects on biofilm formation. The 1,2,4‐triazolyl‐benzoylthiourea derivative 4 showed bacteriostatic activity against the Staphylococcus aureus HU25 clinical strain with an minimum inhibitory concentration (MIC) of 16 µg.mL‐1, which is below the toxic concentration (at 2,500 µg.mL‐1, 62.25% of the cells remained viable). Compound 4 also effectively prevented biofilm formation at the three subinhibitory concentrations tested (1/2 MIC, 1/4 MIC and 1/8 MIC) as confirmed by SEM. For breakdown of formed biofilms, the main influence was at a subinhibitory concentration (1/2 MIC). These findings make compound 4 a strong candidate for studies on the development of new antimicrobial and antibiofilm agents.
- 15 June 2020
- Published by Wiley in Cytopathology
- Vol. 32 (5) , 617-620
Cytopathology smears from autopsies: A viable storage method for molecular analysis
Introduction: Cytology appears to be a viable option to histological samples for proper storage and maintenance of autopsy material for DNA extraction and analysis. In the present study, we tested the feasibility of using archived air‐dried smears produced at the time of the autopsy for simple molecular analysis, comparing quantity and quality of the DNA extracted from the smears to that of correspondent histological specimens.Methods: Air‐dried cytological smears were obtained from scrapings of exactly the same areas collected for histological study. DNA was extracted using a commercially available protocol from all samples, with calculation of purity ratio and overall concentration. The integrity of the extracted DNA was also verified through conventional polymerase chain reaction (PCR).Results: Five cases of lung tumours (2 small cell carcinomas and 3 adenocarcinomas) were collected. Percentage of tumour cells and necrosis ranged from 30% to 90% and from 10% to 40%, respectively, in the cytological preparations, and from 50% to 90% and from 10% to 80%, respectively, in the histological preparations. Purity ratio (260/280) had a median of 1.87 in cytology vs 1.94 in histology. Mean DNA concentration among the cytological preparations was 2653 ng/mL (range 1684‐3980 ng/mL) vs 757.2 ng/mL among the histological preparations (range 456‐1829 ng/mL. DNA from all five cases of cytology was successfully amplified by conventional PCR, in contrast to none from the histology specimens.Conclusions: Archived air‐dried smears scraped from tumoural lesions in autopsies have proven to yield a good concentration of quality DNA for conventional PCR, with better results than formalin‐fixed paraffin embedded material.
- 15 June 2020
- Published by Wiley in Cytopathology
- Vol. 32 (5) , 617-620
Cytopathology smears from autopsies: A viable storage method for molecular analysis
Introduction: Cytology appears to be a viable option to histological samples for proper storage and maintenance of autopsy material for DNA extraction and analysis. In the present study, we tested the feasibility of using archived air‐dried smears produced at the time of the autopsy for simple molecular analysis, comparing quantity and quality of the DNA extracted from the smears to that of correspondent histological specimens.Methods: Air‐dried cytological smears were obtained from scrapings of exactly the same areas collected for histological study. DNA was extracted using a commercially available protocol from all samples, with calculation of purity ratio and overall concentration. The integrity of the extracted DNA was also verified through conventional polymerase chain reaction (PCR).Results: Five cases of lung tumours (2 small cell carcinomas and 3 adenocarcinomas) were collected. Percentage of tumour cells and necrosis ranged from 30% to 90% and from 10% to 40%, respectively, in the cytological preparations, and from 50% to 90% and from 10% to 80%, respectively, in the histological preparations. Purity ratio (260/280) had a median of 1.87 in cytology vs 1.94 in histology. Mean DNA concentration among the cytological preparations was 2653 ng/mL (range 1684‐3980 ng/mL) vs 757.2 ng/mL among the histological preparations (range 456‐1829 ng/mL. DNA from all five cases of cytology was successfully amplified by conventional PCR, in contrast to none from the histology specimens.Conclusions: Archived air‐dried smears scraped from tumoural lesions in autopsies have proven to yield a good concentration of quality DNA for conventional PCR, with better results than formalin‐fixed paraffin embedded material.
- 18 March 2020
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 20 (3) , 227-243
Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications
The phenylamino-pyrimidine (PAP) nucleus has been demonstrated to be useful for the development of new drugs and is present in a wide variety of antiretroviral agents and tyrosine kinase inhibitors (TKIs). This review aims to evaluate the application of PAP derivatives in drugs and other bioactive compounds. It was concluded that PAP derivatives are still worth exploring, as they may provide highly competitive ATP TKI’s with nano/picomolar activity.
- 18 March 2020
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 20 (3) , 227-243
Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications
The phenylamino-pyrimidine (PAP) nucleus has been demonstrated to be useful for the development of new drugs and is present in a wide variety of antiretroviral agents and tyrosine kinase inhibitors (TKIs). This review aims to evaluate the application of PAP derivatives in drugs and other bioactive compounds. It was concluded that PAP derivatives are still worth exploring, as they may provide highly competitive ATP TKI’s with nano/picomolar activity.
- Open Access
- 24 April 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep46772
Correction: Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Scientific Reports 7: Article number: 40920; published online 18 January 2017; updated on 24 April 2017 The Competing Financial Interests section in this Article is incorrect and should read: “Dr. Karin Brüning is a member of the BMK consortium, able to produce sofosbuvir”.
- 24 April 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep46772
Open AccessCorrection: Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Scientific Reports 7: Article number: 40920; published online 18 January 2017; updated on 24 April 2017 The Competing Financial Interests section in this Article is incorrect and should read: “Dr. Karin Brüning is a member of the BMK consortium, able to produce sofosbuvir”.
- 10 August 2010
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 63 (8) , 1307
Tribromoisocyanuric Acid (TBCA)
This paper provides a description of tribromoisocyanuric acid (TBCA), a new reagent used as a source of electrophilic bromine (Br+) in organic synthesis, including in Green Chemistry procedures. Its applications embrace the bromination of alkenes, ß-dicarbonyl compounds and deactivated arenes, as well as oxidations of urazoles, bisurazoles, and thiols.
- 10 August 2010
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 63 (8) , 1307
Tribromoisocyanuric Acid (TBCA)
This paper provides a description of tribromoisocyanuric acid (TBCA), a new reagent used as a source of electrophilic bromine (Br+) in organic synthesis, including in Green Chemistry procedures. Its applications embrace the bromination of alkenes, ß-dicarbonyl compounds and deactivated arenes, as well as oxidations of urazoles, bisurazoles, and thiols.